CN109922812A - 减少与甲状腺相关的副作用的方法 - Google Patents

减少与甲状腺相关的副作用的方法 Download PDF

Info

Publication number
CN109922812A
CN109922812A CN201780068418.8A CN201780068418A CN109922812A CN 109922812 A CN109922812 A CN 109922812A CN 201780068418 A CN201780068418 A CN 201780068418A CN 109922812 A CN109922812 A CN 109922812A
Authority
CN
China
Prior art keywords
days
alkyl
optionally
optionally replaced
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780068418.8A
Other languages
English (en)
Chinese (zh)
Inventor
布瑞恩·丽安
赫罗科·马萨默纳
马克·埃里翁
布鲁斯·伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viking Treatment Co
Metabasis Therapeutics Inc
Original Assignee
Viking Treatment Co
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Treatment Co, Metabasis Therapeutics Inc filed Critical Viking Treatment Co
Publication of CN109922812A publication Critical patent/CN109922812A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
CN201780068418.8A 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法 Pending CN109922812A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396025P 2016-09-16 2016-09-16
US201662396015P 2016-09-16 2016-09-16
US62/396,025 2016-09-16
US62/396,015 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Publications (1)

Publication Number Publication Date
CN109922812A true CN109922812A (zh) 2019-06-21

Family

ID=61619247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780068418.8A Pending CN109922812A (zh) 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法

Country Status (9)

Country Link
US (1) US20190255080A1 (enExample)
EP (1) EP3512523A4 (enExample)
JP (2) JP2019531346A (enExample)
KR (2) KR20240074912A (enExample)
CN (1) CN109922812A (enExample)
AU (1) AU2017327383B2 (enExample)
CA (1) CA3037146A1 (enExample)
MX (2) MX2019003032A (enExample)
WO (1) WO2018053036A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457346A (zh) * 2019-08-19 2021-03-09 苏州闻天医药科技有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
AU2017363206A1 (en) 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR TREATMENT OF FIBROSE
MX2020009843A (es) 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
EP3966240A1 (en) * 2019-05-08 2022-03-16 Novartis AG Anti-cd40 antibodies for use in treatment of t1dm and insulitis
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
WO2021032218A1 (zh) * 2019-08-19 2021-02-25 苏州闻天医药科技有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
JP7670687B2 (ja) * 2020-02-24 2025-04-30 へパジーン セラピューティクス （エイチケイ） リミテッド 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
CN109071577A (zh) * 2016-04-22 2018-12-21 症变治疗公司 甲状腺激素受体激动剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP1525219B1 (en) * 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
WO2006128058A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
AU2009330458B2 (en) * 2008-12-22 2013-08-22 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
AU2017363206A1 (en) * 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
CN109071577A (zh) * 2016-04-22 2018-12-21 症变治疗公司 甲状腺激素受体激动剂及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457346A (zh) * 2019-08-19 2021-03-09 苏州闻天医药科技有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
US20190255080A1 (en) 2019-08-22
JP2022174261A (ja) 2022-11-22
JP7656574B2 (ja) 2025-04-03
MX2019003032A (es) 2019-09-13
KR20190060786A (ko) 2019-06-03
MX2023000887A (es) 2023-02-22
KR20240074912A (ko) 2024-05-28
BR112019005039A2 (pt) 2019-06-25
EP3512523A1 (en) 2019-07-24
NZ751857A (en) 2024-05-31
AU2017327383A1 (en) 2019-04-11
JP2019531346A (ja) 2019-10-31
AU2017327383B2 (en) 2023-06-29
WO2018053036A1 (en) 2018-03-22
CA3037146A1 (en) 2018-03-22
EP3512523A4 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
CN109922812A (zh) 减少与甲状腺相关的副作用的方法
US11376251B2 (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US4708868A (en) Oral anti-diabetic pharmaceutical forms and the preparation thereof
KR20210137046A (ko) 담즙정체의 치료 방법
KR910004571B1 (ko) 경구용 당뇨병치료 제제를 제조하는 방법
TW202202139A (zh) 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重
US20080234230A1 (en) Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator
CA3077514C (en) Delayed release deferiprone tablets and methods of using the same
TW201136916A (en) New uses
CN120091814A (zh) 用slc6a19功能的哌啶抑制剂治疗pku的给药方案
JPH0733332B2 (ja) 痴呆症状改善・治療剤
US6008222A (en) Method for oral administration of buspirone and nefazodone
JP2000204037A (ja) 筋萎縮性側索硬化症治療薬
JPH07118148A (ja) 肝癌予防剤
US20110280941A1 (en) Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes
JPH02218610A (ja) 骨疾患の予防および治療剤
JP2835547B2 (ja) 糖尿病治療剤
US20250312331A1 (en) Compositions and methods for administering paltusotine to patients with hepatic impairment
WO2026002224A1 (en) Method of treating polycystic ovary syndrome
JP2024165859A (ja) 掌蹠膿疱症の治療用医薬組成物
CN117298111A (zh) 一种酰胺类化合物在制备治疗骨质疏松药物中的应用
CN101198326A (zh) Ⅱ型糖尿病治疗用的组合药物制剂
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
JP2621382B2 (ja) 尿酸排泄剤
JP2017128545A (ja) 併用医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination